文献速递乳房整形与再造

脱细胞真皮基质辅助的假体乳房重建:SurgiMend PRS、AlloDerm与DermACELL的比较

Acellular Dermal Matrix-Assisted, Prosthesis-Based Breast Reconstruction: A Comparison of SurgiMend PRS, AlloDerm, and DermACELL.
PubMed 文献 · Ann Plast Surg · 2024-01-01

本研究为多中心回顾性综述,纳入2014年1月至2022年7月间738例(1228侧乳房)行即刻假体乳房重建并使用SurgiMend PRS、AlloDerm或DermACELL的患者。结果显示三种脱细胞真皮基质在短期并发症、总重建失败、90天内再手术、包膜挛缩及非计划取出率上相当,多因素分析中脱细胞真皮基质类型并非任何结局的独立预测因素。患者特征和手术方式可能比脱细胞真皮基质衍生物本身更能预测术后结局。

要点

  • 三种脱细胞真皮基质(SurgiMend PRS、AlloDerm、DermACELL)在即刻假体乳房重建中的并发症率和重建失败率相当。
  • 多因素分析中脱细胞真皮基质类型不是任何结局的独立预测因素。
  • 体重指数、糖尿病、吸烟史、新辅助和辅助化疗、辅助放疗、保留皮肤乳房切除术、Wise模式及乳晕周围切口、组织扩张器使用和胸肌下平面置入是术后并发症的显著预测因素。

核心结论

  • 低并发症率支持胎牛来源和人来源脱细胞真皮基质在即刻假体乳房重建中的等效性。
  • 患者特征和手术方式可能比脱细胞真皮基质衍生物本身更能预测术后结局。

研究设计与样本

  • 多中心回顾性综述,纳入2014年1月至2022年7月期间行即刻假体乳房重建并使用SurgiMend PRS(胎牛来源)、AlloDerm(人来源)或DermACELL(人来源)的患者。
  • 共738例患者(1228侧乳房),其中405例(54.9%)接受DermACELL,231例(31.3%)接受AlloDerm,102例(13.8%)接受SurgiMend PRS。

主要发现

  • 短期并发症、总重建失败、90天内再手术、包膜挛缩及非计划取出率在三种脱细胞真皮基质间相当。
  • 多因素分析校正基线差异后,脱细胞真皮基质类型不是任何关注结局的独立预测因素。
  • 体重指数、糖尿病、吸烟史、新辅助和辅助化疗、辅助放疗、保留皮肤乳房切除术、Wise模式及乳晕周围切口、组织扩张器使用和胸肌下平面置入是术后并发症的显著预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acellular dermal matrices (ADMs) are frequently employed in immediate prosthesis-based breast reconstruction (iPBR) to provide structural support. Despite differences in ADM derivatives, few studies directly compare their outcomes in the setting of iPBR. We sought to conduct a large head-to-head study comparing 3 ADMs used across our institution. METHODS: A multicenter retrospective review of patients undergoing iPBR with SurgiMend PRS (fetal bovine-derived; Integra Lifesciences, Princeton, NJ), AlloDerm (human-derived; LifeCell Corp, Bridgewater, NJ), or DermACELL (human-derived; Stryker Corp, Kalamazoo, MI) between January 2014 to July 2022 was performed. Primary outcomes included rates of unplanned explantation and total reconstructive failure. Secondary outcomes included 90-day postoperative complications and long-term rates of capsular contracture development. RESULTS: A total of 738 patients (1228 breasts) underwent iPBR during the study period; 405 patients received DermACELL (54.9%), 231 received AlloDerm (31.3%), and 102 received SurgiMend PRS (13.8%). Rates of short-term complications, total reconstruction failure, reoperation within 90 days, capsular contracture, and unplanned explantation were comparable. These findings remained true upon multivariate analysis accounting for baseline differences between cohorts, whereby ADM type was not an independent predictor of any outcome of interest. Conversely, factors such as body mass index, diabetes mellitus, smoking history, neoadjuvant and adjuvant chemotherapy, adjuvant radiation, skin-sparing mastectomy, Wise pattern and periareolar incisions, use of tissue expanders, and a subpectoral plane of insertion were significant predictors of postoperative complications. CONCLUSION: Low rates of complications support the equivalency of fetal bovine and human-derived ADMs in iPBR. Patient characteristics and operative approach are likely more predictive of postoperative outcomes than ADM derivative alone.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Berger LE, Spoer DL, Huffman SS, et al. Acellular Dermal Matrix-Assisted, Prosthesis-Based Breast Reconstruction: A Comparison of SurgiMend PRS, AlloDerm, and DermACELL. Ann Plast Surg. 2024. PMID: 38885163. doi:10.1097/SAP.0000000000003990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。